Intermittent Roxithromycin for Preventing Progression of Small Abdominal Aortic Aneurysms: Long-Term Results of a Small Clinical Trial

Høgh, Annette; Vammen, Sten; Østergaard, Lars; Joensen, Jette; Henneberg, E W; Lindholt, Jes Sanddal

doi:10.1177/1538574409335037

Cited by 37 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They showed that the expansion rate of AAAs treated with doxycycline was slower than with placebo, but the difference did not reach statistical significance [ 54 ]. Treatment with roxithromycin, a macrolide antibiotic, significantly reduced the AAA expansion rate [ 55 , 56 ]. However, it is not clear whether the effect was due to its anti-microbial or anti-inflammatory activities.…”

Section: Current Statusmentioning

confidence: 99%

Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm

Yoshimura

Morikage

Nishino-Fujimoto

et al. 2018

CDT

View full text Add to dashboard Cite

Background: Abdominal aortic aneurysm (AAA), a common disease involving the segmen-tal expansion and rupture of the aorta, has a high mortality rate. Therapeutic options for AAA are cur-rently limited to surgical repair to prevent catastrophic rupture. Non-surgical approaches, particularly pharmacotherapy, are lacking for the treatment of AAA.Objective: We review both basic and clinical studies and discuss the current challenges to developing medical therapy that reduces AAA progression.Results: Studies using animal models of AAA progression and human AAA explant cultures have identified several potential targets for preventing AAA growth. However, no clinical studies have con-vincingly confirmed the efficacy of any pharmacologic treatment against the growth of AAA. Thus, there is as yet no strong recommendation regarding pharmacotherapy to reduce the risk of AAA pro-gression and rupture.Conclusion: This review identifies concerns that need to be addressed for the field to progress and dis-cusses the challenges that must be overcome in order to develop effective pharmacotherapy to reduce AAA progression in the future.

show abstract

Section: Current Statusmentioning

confidence: 99%

Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm

Yoshimura

Morikage

Nishino-Fujimoto

et al. 2018

CDT

View full text Add to dashboard Cite

show abstract

“…13 The second study, also a small RCT, reported a borderline effect of a 4 week treatment with roxithromycin on AAA progression (p ¼ .055). 33 The effect of azithromycin, another member of the macrolide class, was investigated in a larger RCT conducted by Karlsson et al 34 in 2009 (n ¼ 247). This study did not observe a significant difference between the AAA expansion rate in the azithromycin treated patients and controls.…”

Section: Statinsmentioning

confidence: 99%

Editor's Choice – Pharmaceutical Management of Small Abdominal Aortic Aneurysms: A Systematic Review of the Clinical Evidence

Kokje

Hamming

Lindeman

2015

European Journal of Vascular and Endovascular Surgery

View full text Add to dashboard Cite

show abstract

“…Thus, although the exact role of C. pneumoniae in pathogenesis of aortic aneurysm remains to be clarified, the results of several prospective clinical trials could provide some contribution to this matter. It has been proven, that antibiotics effective against C. pneumoniae -tetracyclines (doxycyclin) and macrolides (roxithromycin, but not azithromycin), may reduce the progression of small aortic aneurysm (Høgh et al, 2009, see also chapter 3.5.2.2). Based on mentioned observations one can expect a direct correlation between the presence of C. pneumoniae and tissue levels of MMPs in aneurismal aortic wall specimens.…”

Section: Chlamydia Pneumoniae and Mmps In Aortic Aneurysmmentioning

confidence: 99%

Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture

Grundmann¹

2011

View full text Add to dashboard Cite

Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published articles. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book.

show abstract

Intermittent Roxithromycin for Preventing Progression of Small Abdominal Aortic Aneurysms: Long-Term Results of a Small Clinical Trial

Abstract: Annual 4 week treatment with 300 mg roxithromycin daily may reduce the progression of small AAAs, and later need for surgical repair. However, more robust studies are needed for confirmation.

Cited by 37 publications

References 29 publications

Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm

Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm

Editor's Choice – Pharmaceutical Management of Small Abdominal Aortic Aneurysms: A Systematic Review of the Clinical Evidence

Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture

Contact Info

Product

Resources

About